Glioblastoma is the most common and most fatal primary malignant brain tumor in adults. Despite progress in characterizing the genetic and molecular mechanisms of glioblastomas, advances in treatment that translate into substantial improvement in prognosis have yet to be realized. A role for cytomegalovirus in glioblastoma pathogenesis was proposed more than a decade ago and has generated considerable debate as a possible therapeutic target. Independent groups have had variable success in detecting cytomegalovirus infection in tumor cells; the overall consensus is that very low levels of viral proteins and nucleic acids can be observed. Although cytomegalovirus has not been found to be oncogenic in this context, a possible oncomodulatory role has been suggested. A recent clinical trial evaluating valganciclovir as an adjuvant therapy for the treatment of glioblastoma did not demonstrate a beneficial effect on tumor growth or overall survival, although retrospective analysis subsequently indicted a significant survival benefit. In light of the publicity of that report, patients and neuro-oncologists are requesting cytomegalovirus testing to justify antiviral treatment. Based on questions on the significance of cytomegalovirus infection in glioblastomas and the lack of a clear clinical benefit of valganciclovir, we reviewed this topic and conclude that, at this time, there is insufficient evidence to recommend routine testing and treatment.
INTRODUCTION
Glioblastomas (GBMs) are World Health Organization Grade IV gliomas that can either progress from lower-grade gliomas (World Health Organization Grade II/III astrocytomas and oligoastrocytomas; 10%) or arise de novo (90%) (1). The incidence is approximately 5 per 100,000 person-years, increasing with age, with a peak from 45 to 75 years. The most common sites of occurrence are the cerebral hemispheres (parietal and frontal lobes 9 occipital lobes), although other areas of the brain are often involved. Presenting symptoms include new-onset seizures, behavioral changes, motor deficits, and signs of increased intracranial pressure such as headaches. Average survival is 12 to 15 months with surgical resection, radiation, and temozolomide treatment (2) . Significant progress has been made in understanding the molecular pathogenesis of GBMs, including the identification of genetic alternations in TP53, receptor tyrosine kinases, and retinoblastoma pathways (3) . However, advances in treatment and survival have been limited, and motivation continues to develop novel therapeutic strategies. An understanding of etiologic triggers underlying GBM development could be useful for designing treatment.
Known risk factors for the development of GBM and other tumor types elsewhere in the body (e.g., meningioma and sarcoma) include previous exposure to high-dose irradiation, which is thought to induce DNA breakage and cell cycle abnormalities across time (2) . In systemic neoplasia, there are well-established precedents for oncogenesis after specific tissue infections (e.g. Epstein-Barr virus in Burkitt lymphoma, human papilloma virus in cervical cancer, hepatitis B virus in hepatocellular carcinoma, and Helicobacter pyloriYassociated gastric cancer) (4Y7). By analogy, questions on the involvement of viral agents in GBM etiology and on the potential for viable targets for GBM intervention have arisen (8) .
Several viral pathogens have been proposed to play a role in GBM pathogenesis. Mice injected with JC virusVthe human polyoma virus most associated with progressive multifocal leukoencephalopathyVhave been reported to develop malignant gliomas, and SV40 has been identified in human GBMs (9, 10) . In addition, hamsters injected with BK virus, another human polyoma virus, have been reported to develop ependymomas (11) . More recently, evidence has implicated human cytomegalovirus (HCMV) as an associated factor in high-grade gliomas, an idea that has generated considerable interest and controversy (12, 13) .
Human cytomegalovirus (human herpes virus-5) is a 235-kb double-strand DNA virus that encodes more than 200 proteins (14) . Approximately 50% to 80% of adults have been infected, as indicated by the presence of serum IgG antibodies. Cells with productive (lytic) infection are large and contain single basophilic nuclear inclusions with a clear halo. Primary infection in the immunocompetent host is typically asymptomatic, although a mononucleosis-like syndrome can occur. Virus reactivation in immunosuppressed individuals can cause a variety of symptoms (including pneumonia, hepatitis, colitis, encephalitis, and retinitis) and can be life-threatening.
Here, we review evidence for the presence and significance of HCMV in gliomas, the role of HCMV proteins in pathogenesis, and the utility of targeting HCMV in glioma treatment. These questions are directly relevant to current practice because neuro-oncologists and patients are increasingly requesting analysis of individual tumors as part of personalized (or ''precision'') medicine.
DETECTION OF HCMV IN GBM TUMOR CELLS
The presence of HCMV in high-grade gliomas was first reported by Cobbs et al (12) in 2002 (Table) . Immunohistochemistry (IHC) of formalin-fixed paraffin-embedded tissue showed staining with antibodies against HCMV-encoded proteins immediate early antigen-1 (IE1; 72 kDa), pp65 tegument protein, and p52/76-kDa early DNA-binding protein and early protein (IE/EA). This signal was present both in the cytoplasm and in the nuclei of tumor cells, but not in areas of vascular proliferation, necrosis, or normal brain tissue. Characteristic nuclear inclusions were not identified, and special optimization of IHC conditions was reported to be necessary for detecting low levels of proteins. In situ hybridization (ISH) yielded positive results for HCMV messenger RNA and DNA in gliomas, but not in normal brain or in other neurologic disorders. Electron microscopy showed pp65-positive particles. Based on these results, Cobbs et al (12) hypothesized that HCMV plays a role in GBM pathogenesis, although they believed that there was insufficient evidence to conclude that viral activity was caused by either primary infection or reactivation in the context of local immunosuppression.
Subsequent reports from independent groups have had mixed success in reproducing the results from the initial study (Table) . No HCMV was detected by pp65 or p52/76-kDa IHC, ISH, or polymerase chain reaction (PCR) in a series of 22 brain tumors, including GBMs (15). Another investigation described staining of ''nontumor astrocyte-like cells'' only in 10 of 97 (10%) GBMs by anti-IE1 IHC and DNA ISH (16) . In another study, 0 of 40 gliomas had detectable HCMV DNA in brain tissue or blood samples, or proteins by IHC (17) . Conversely, 42 of 45 (93%) GBMs were reported to have IE1 IHC staining, 30 of 33 (91%) had pp65 IHC staining, and 16 selected cases had HCMV DNA by ISH (18) . Immediate early antigen-1 IHC staining was also reported in 44 of 50 gliomas (88%), and a correlation existed between the number of positive cells and high tumor grade (GBM, 79%; lower-grade gliomas, 48%) (19) . The discrepancies between these studies have been attributed to differences in the sensitivities of viral detection. Optimized antigen retrieval and high antibody concentration are thought to be the key factors required for IHC detection of low-level latent HCMV infection in brain tissue. Of note, these steps are unnecessary for detection of active infection in other tissues such as lung tissues, which are commonly used as positive controls in many clinical IHC laboratories.
Given the discordance among reported results and uncertainty of the importance of analysis for the treatment of HCMV in patients with glioma, a consensus conference on the role of HCMV in GBM was held in 2011. The participants concluded that there was sufficient evidence that HCMV nucleic acids and proteins were present in most malignant gliomas (29) . However, a lingering issue was the lack of HCMV sequences detected by unbiased next-generation sequencing platforms. For example, a recent study identified Epstein-Barr virus and roseolovirus in unmapped reads of 21 GBMs, but no HCMV sequences were identified (26) .
In response to patient and clinician requests at our institution and because of our interest in validating the published techniques in our own laboratory, we undertook to determine the incidence of HCMV infection in our patient population. A tissue microarray of 68 independent GBM samples was stained with anti-cytomegalovirus (CMV) antibody cocktail CCH2/DDG9 corresponding to p52/76-kDa proteins, considered an epitope comparable to those used by other groups. We found no positive staining in our GBM cohort (0/68), with appropriate (and thus presumed ''optimized'') staining in a positive control (active CMV infection of the lung) (Table) . Based on these findings, we concluded that either 1) HCMV infection was not a feature of these 68 tested tumors or 2) HCMV protein content was below the level of detection in our clinical IHC laboratory.
CORRELATION OF HCMV DETECTION WITH PROGNOSIS IN GBM
The prognostic significance of HCMV in GBM has also been investigated and remains unclear. No differences in progression-free survival were found among patients with GBMs, whether they showed positive IHC staining of IE1 or pp65 or had detectable HCMV DNA in tumor tissue or blood (27) . Increased overall survival was reported for low-grade tumors (defined by IE1 IHCYpositive cells G25%) compared with high-grade tumors (13 vs 33 months, p = 0.036), whereas no difference in disease-free survival was found (24) . It is unclear whether the correlation between a greater number of IHC-positive cells and longer survival is caused by increased viral reactivation by a more immunosuppressive tumor, oncomodulatory properties of HCMV causing a more aggressive phenotype, or an artifact of intratumoral variability in staining.
POTENTIAL ROLE FOR HCMV IN GBM PATHOGENESIS
Recent reviews have focused on how various HCMV proteins could contribute to GBM pathogenesis through overlap of cancer hallmark activities, including promotion of cell survival, proliferation, and angiogenesis (29, 30) . Amplification of the receptor tyrosine kinase platelet-derived growth factor receptor-> (PDGFRA), which activates the PI(3)K/Akt pathway leading to inhibition of apoptosis, is commonly seen in GBMs. PDGFRA has been shown to be required for HCMV cell entry (via binding of HCMV blycoprotein B) and for IE1 expression and infectious virus production (31) . Tumors with PDGFRA amplification would therefore be expected to have higher rates of HCMV infection. An increase in human telomerase activity has been demonstrated in cultured fibroblasts and glioma cell lines with HCMV infection or HCMV IE1 expression, which would be expected to increase cell survival (32) . Human cytomegalovirus pp71 seems to colocalize with stem cell factor in GBMs, and pp71 expression has been shown to induce capillary formation in a stem cell factorYdependent manner indicative of angiogenesis (33) . The glioma mouse model Mut3 (GFAP-cre;Nf1 loxP/+ ; Trp53 j/+ ) has been used to study the effects of murine CMV (MCMV) on tumors in vivo (34) . Newborn Mut3 mice infected with MCMV were shown to clear active infection by Postnatal Day 56 but had decreased overall survival compared with mock-infected mice (26.7 vs 34.1 weeks, p = 0.0003). Signal transducer and activator of transcription-3 (STAT3) phosphorylation was found to be increased in MCMVinfected Mut3 mice (and in GBM neurospheres infected with HCMV), leading to transcriptional activity involved with immune evasion, angiogenesis, and cell proliferation.
ONCOMODULATORY FACTORS
The body of data thus far does not support a role for HCMV in the genesis of GBMs, and the presence of detectable viral proteins and nucleic acids is likely caused by reactivation in the setting of local immunosuppression. The evidence is consistent with an oncomodulatory role for HCMV, in which the virus affects cancer cell function without being directly involved in malignant transformation (35, 36) . As discussed previously, mice with mutations in TP53 and Nf1 genes have shown decreased glioma-associated survival from MCMV infection by a STAT3-associated mechanism (34) . Signal transducer and activator of transcription-3 can be activated by HCMV through at least 3 mechanisms, including 1) secretion of interleukin-6 by HCMV-infected cells via the interleukin-6RYJanus kinaseYSTAT3 pathway; 2) expression of the constitutively active HCMV chemokine receptor US28, which phosphorylates STAT3; and 3) HCMV glycoprotein B signaling through the PDGFRAYJanus kinaseYSTAT3 axis (37, 38) . Increased STAT3 signaling leads to cell cycle progression, which is dysregulated in GBMs owing to mutation of TP53. Other common mutations in GBM include loss of PTEN and Nf1 functions, which inhibit the receptor tyrosine kinases Ras and phosphoinositide-3-kinase, respectively. These downstream effects of HCMV glycoprotein BYactivated PDGFRA lead to activation of Raf and AKT and, consequently, to proliferation and inhibition of apoptosis. Whether targeting HCMV proteins will translate into improved clinical outcomes has yet to be determined.
IS THERE A ROLE FOR ANTI-CMV THERAPEUTICS IN GBM TREATMENT?
In light of unresolved issues surrounding HCMV detection and prognosis, the most direct method for proving the clinical significance of HCMV in GBMs would be to study the effects of targeting HCMV in human subjects. The ideal study would compare incidence of GBM and survival in vaccinated and unvaccinated cohorts; however, no HCMV vaccine is currently available (39) . In addition, the vast differences in incidence between HCMV infection and GBM occurrence (80% vs 0.00005%) would require a prohibitively large sample size to see an effect.
Owing to our current inability to prevent or cure HCMV infection, the best available therapy consists of treatment with small molecules that suppress viral replication. Valganciclovir is the orally administered form of ganciclovir, an antiviral drug with anti-CMV activity. Ganciclovir is phosphorylated by the virus-encoded protein kinase UL97 and cellular kinases, and acts by competitively inhibiting viral DNA polymerases and by serving as a poor substrate for chain elongation. The Valcyte Treatment of Glioblastoma Patients in Sweden (VIGAS) study was conducted to test the safety and efficacy of valganciclovir in 42 patients with GBM (13) . Participants were randomized to receive valganciclovir (n = 22) or placebo (n = 20) for 6 months, in addition to standard therapy. After 6 months, patients from either group could choose to take valganciclovir and were followed for a total of up to 24 months. No differences in tumor volume, progression-free survival, or overall survival were found between the valganciclovir group and the placebo treatment group. Stragliotto et al (13) suggested that the lack of efficacy in the trial was caused by limitations in the study design, including insufficient subjects and allowed cross-over between groups.
A subsequent report from the same group has generated significant publicity and controversy (40) . In addition to the participants in the VIGAS study, 28 additional patients received valganciclovir, and a 2-year survival rate of 62% was reported compared with 18% in contemporary controls (median overall survival, 25.0 versus 13.5 months, p G 0.001). This retrospective analysis has been heavily criticized based on the selection of additional patients, the limited characterization of contemporary controls, and the methods of detecting HCMV infection (41, 42) . The critical issue that severely limits the validity of this report is apparent enrichment of the treatment group by inclusion of patients with better prognostic factors. Specifically, several additional patients who were included first had to survive long enough to cross-over from the original placebo group, whereas others were selected outside the study for valganciclovir treatment only in the absence of progressive disease. The 50 valganciclovir-treated patients were then compared with 137 contemporary controls reported to have received a similar baseline therapy, but description of these subjects is limited. The overall survival of the VIGAS patients (treatment and control groups) was reported to be higher than that of contemporary controls (17.7 vs 13.7 months, p = 0.0261) (13), suggesting possible bias in the study participants and further confounding the differences on follow-up analysis. A comparatively minor issue is the use of IE1 IHC to detect HCMV viral infection. Only 71% of the VIGAS participants had HCMV-specific serum IgG antibodies, highlighting the discrepancy of clinically undetectable extratumoral HCMV. No analysis of survival among these IgG-positive subjects was performed.
Cidofovir is an alternative antiviral agent with anti-HCMV activity that is delivered intravenously. Similar to valganciclovir/ganciclovir, cidofovir acts by inhibiting viral DNA polymerase but does not require activation by a viral kinase. The effects of cidofovir on athymic mice intracranially inoculated with GBM cell lines were investigated (43) . With or without HCMV infection, mice survived longer with cidofovir than with placebo, and the effects were enhanced by combined treatment with radiation. Hadaczek et al (43) hypothesized that the HCMV-independent effects of cidofovir are attributable to its incorporation into the DNA of dividing tumor cells, leading to double-strand breaks and apoptosis. Whether these results will translate into human GBMs has yet to be investigated.
CONCLUSIONS
For more than a decade, the clinical relevance of HCMV infection to GBM pathogenesis has been widely debated. Conflicting reports on the ability to detect HCMV proteins and nucleic acids in GBMs continue to be published, although there is a general consensus that viral activity is well below the limits of standard diagnostic tests. There is no current evidence for a role of HCMV in tumorigenesis, yet considerable data on possible oncomodulatory functions for various viral proteins have accumulated. Clinical trials thus far have shown no benefit from treating GBMs with antiviral agents. Based on current evidence, routine testing for HCMV and antiviral therapy at this time is not supported for GBM patients. Further basic and well-designed clinical studies are required to address the remaining unanswered questions on this issue.
